Duration of Androgen Deprivation Therapy in High-risk Prostate Cancer: A Randomized Phase III Trial

In this study, we report outcomes from high-risk prostate cancer patients treated with radiotherapy and either 36 or 18 mo of androgen deprivation therapy. There was no difference in survival between the two groups, with the 18-mo group experiencing a better quality of life.